Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
April 19 2021 - 4:47PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of April 2021
Commission File Number: 001-38547
Autolus Therapeutics plc
(Translation of registrants name into English)
Forest House
58 Wood Lane
White City
London W12
7RZ
United Kingdom
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form
20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Separation of the Roles of Chairman of the Board and Chief Executive Officer; Appointment of New
Chairman of the Board
On April 19, 2021, Autolus Therapeutics plc (the Company) announced that the Companys
Board of Directors (the Board) has determined that as the Companys lead program AUTO1 continues to progress in multiple clinical trials and the Company starts to prepare for commercialization in the event that AUTO1
receives marketing approval, the complexity of the business warrants separation of the roles of chairman and chief executive officer. Consequently, the Board has appointed Dr. Martin Murphy as the non-executive chairman of the Board, effective
April 15, 2021, enabling Dr. Christian Itin, the Companys chief executive officer, to fully focus on leading the business. Dr. Itin will continue to serve as a member of the Board. A copy of the press release is filed as Exhibit 99.1 to
this Report and is incorporated by reference herein.
The information contained in this Report, but excluding Exhibit 99.1, is hereby incorporated by
reference into the Companys Registration Statement on Form F-3 (File No. 333-232690) and the Companys Registration Statement on Form S-8 (File No. 333-226457).
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
AUTOLUS THERAPEUTICS PLC
|
|
|
|
|
Date: April 19, 2021
|
|
|
|
By:
|
|
/s/ Christian Itin
|
|
|
|
|
Name
|
|
Christian Itin, Ph.D.
|
|
|
|
|
Title:
|
|
Chief Executive Officer
|
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Apr 2023 to Apr 2024